DCGI Gives Import and Market Permission to AstraZeneca for Inhalation Powder to Treat Asthma
DSIJ Intelligence / 16 Jun 2017
The Drug Controller General of India (DCGI) has given import and market permission in Form 45 (Market Authorization) to AstraZeneca Pharma
The Drug Controller General of India (DCGI) has given import and market permission in Form 45 (Market Authorization) to AstraZeneca Pharma, the company informed the bourses on Thursday.
AstraZeneca Pharma India Limited is a global bio pharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cancer and respiratory disease,cardiovascular/metabolic disease, inflammatory and autoimmune disease.
This permission is for FDC of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder (Symbicort® Turbuhaler® 320/9 µg). It is a product of AstraZeneca global and is indicated in the regular treatment of asthma.
Meanwhile, at Rs 931.05 per share at 1020 hours IST on BSE, AstraZeneca Pharma was up by 1.2%. The stock hit a high of Rs 955.65 and a low of Rs 930, so far during the morning session.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.